Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial oxidative damage is not a discrete molecule or receptor, but refers to the cellular injury resulting from excess ROS generated by the mitochondrial electron transport chain, particularly at complexes I and III, overwhelming native antioxidant defenses. This process causes modification and degradation of mitochondrial DNA, proteins, and lipids, leading to loss of mitochondrial function, impairment of ATP production, activation of cell death pathways, and is implicated as a central driver in aging, neurodegenerative conditions, cardiovascular disorders, cancer, and other pathologies. Therapeutic strategies often aim at scavenging mitochondrial ROS or boosting mitochondrial antioxidant defenses, though clinical efficacy remains limited due to biological complexity.
Reduction of mitochondrial ROS formation Enhancement of mitochondrial antioxidant capacity Prevention of oxidative biomolecule damage
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial oxidative damage.